Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression

Neurology

Volumn 84, Issue 5, 2015, Pages 508-515

  Caroli, Anna ^a   Prestia, Annapaola ^b   Galluzzi, Samantha ^b   Ferrari, Clarissa ^b   Van Der Flier, Wiesje M ^c   Ossenkoppele, Rik ^c   Van Berckel, Bart ^c   Barkhof, Frederik ^c   Teunissen, Charlotte ^d   Wall, Anders E ^e   Carter, Stephen F ^f,g   Schöll, Michael ^f,h   Choo, Il Han ^f,i   Grimmer, Timo ^j   Redolfi, Alberto ^b   Nordberg, Agneta ^f,j   Scheltens, Philip ^c   Drzezga, Alexander ^k   Frisoni, Giovanni B ^b,l  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g MedTech West at Sahlgrenska University Hospital Campus   (Sweden)

^h Chosun University College of Medicine   (South Korea)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITY OF COLOGNE   (Germany)

^l UNIVERSITY OF GENEVA   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOENZYME; BIOLOGICAL MARKER; FLUORINE 18;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; GENOTYPE; HIPPOCAMPUS POTENTIAL; HUMAN; MALE; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SUSPECTED NON ALZHEIMER DISEASE PATHOLOGY; AMYLOID PLAQUE; CLINICAL TRIAL; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY; NEURODEGENERATIVE DISEASES; PREDICTIVE VALUE; PSYCHOLOGY; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEURODEGENERATIVE DISEASES; PLAQUE, AMYLOID; PREDICTIVE VALUE OF TESTS;

EID: 84925969089     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001209     Document Type: Article

References (30)

1. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004;62:925-931.
2. Jack CR Jr, Lowe VJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
3. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
4. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013;80:1347-1358.
5. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
6. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765-775.
7. Petersen RC, Aisen P, Boeve BF, et al. Criteria for mild cognitive impairment due to Alzheimer's disease in the community. Ann Neurol 2013;74:199-208.
8. Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative. Biomarker-based prediction of progression in MCI: comparison of AD signature and hippocampal volume with spinal fluid amyloid-b and tau. Front Aging Neurosci 2013;5:55.
9. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on b amyloid in normal elderly. Ann Neurol 2012;73:472-480.
10. Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar β amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012;32:18227-18233.
11. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 2012;11:1048-1056.
12. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
13. Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013;70:1512-1519.
14. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not b-amyloid in cognitively normal older individuals. J Neurosci 2013;33:5553-5563.
15. Chételat G. Alzheimer disease: Ab-independent processes- rethinking preclinical AD. Nat Rev Neurol 2013;9: 123-124.
16. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
17. Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013;80: 1048-1056.
18. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17: 302-316.
19. Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576-1582.
20. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study. Lancet Neurol 2013;12:957-965.
21. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005- 2010. J Neuropathol Exp Neurol 2012;71:266-273.
22. Mattsson N, Andreasson U, Persson S, et al; Alzheimer's Association QC Program Work Group. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013;9:251-261.
23. Giannakopoulos P, Herrmann FR, Bussiere T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60:1495-1500.
24. Barkhof F, Polvikoski TM, van Straaten EC, et al. The significance of medial temporal lobe atrophy: A postmortem MRI study in the very old. Neurology 2007;69: 1521-1527.
25. Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2:a006221.
26. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009;73:1193-1199.
27. Zwan M, van Harten A, Ossenkoppele R, et al. Concordance between cerebrospinal fluid biomarkers and [11C] PIB PET in a memory clinic cohort. J Alzheimers Dis 2014;41:801-807.
28. Del-Campo M, Mollenhauer B, Bertolotto A, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: An update. Biomark Med 2012;6: 419-430.
29. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement Epub May 2, 2014.
30. Prestia A, Caroli A, Herholz K, et al. Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement 2013;9: 677-686.